MSACL 2019 US Abstract

Self-Classified Topic Area(s): Tox / TDM / Endocrine

Tape Stripping and High Performance LC-MS/MS Measuring Chlorhexidine Gluconate on Skin

Xueheng Zhao (1), Joshua Schaffzin (2,3), Jennifer Carson (1), Andrea Ankrum (3), David Haslam (2), Christopher Dandoy (4), Kenneth D.R. Setchell (1,5)
(1) Division of Pathology & Laboratory Medicine, (2) Division of Infectious Disease, (3) Infection Prevention & Control Program, (4) Division of Bone Marrow Transplantation & Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH (5) Department of Pediatrics, University of Cincinnati College of medicine, Cincinnati, OH

Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704

Xueheng Zhao (Presenter)
Cincinnati Children's Hospital Medical Center

Relevant Financial Disclosures (within past 24 months)

No relevant financial relationship(s) to disclose.

Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above.

Conflict mitigation NOT REQUIRED.

Abstract

Chlorhexidine gluconate (CHG) is used widely in healthcare and has been shown to reduce bacterial colonization and central line-associated bloodstream infection (CLABSI) risk in critically ill children and adults. Clinical guidance recommends daily application of CHG on patients with a central venous catheter (CVC) to prevent CLABSI. Due to the lack of suitable analytical method to measure CHG levels on skin, its efficacy and toxicity for patients with CVC are poorly understood. We developed and validated an accurate assay to detect and monitor CHG levels on patient skin using HPLC-MS/MS for clinical analysis.